Opinion|Videos|July 29, 2024
Expert Perspectives in Navigating Treatment Strategies with CDK4/6 Inhibitors in HR+ Breast Cancer
A panel of experts offer perspectives in navigating treatment strategies with CDK4/6 inhibitors.
Advertisement
Episodes in this series
Video content above is prompted by the following:
Treatment options post progression on CDK4/6i + ET
- What is your overall perception on the class of oral SERDs? How will they continue to impact the treatment landscape?
- What are your perceptions on efficacy and safety data? What has your experience been in practice with:
- Elacestrant
ASCO 2024 #1071 : Real-world (RW) elacestrant use patterns and therapeutic outcomes.ASCO 2024 #1064 : Elacestrant plus abemaciclib Preliminary data from ELECTRAASCO 2024 #1069 : Elacestrant in various combinations: Preliminary data from ELEVATEBardia Cancer Res 2023 : GS3-01 EMERALD phase 3 trial of elacestrant vs endocrine therapy: Updated results by duration of prior CDK4/6i in metastatic setting
- Elacestrant
Advertisement
Related to this article
The FDA approved gedatolisib in PIK3CA wild-type breast cancer, granted full approval to selpercatinib in RET fusion+ tumors, and more.
Laure-Anne Teuwen, MD, PhD, debates the real-world advantages of subcutaneous pembrolizumab.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Catch up on insights into the global development of breast cancer treatments in the global spotlight.
The FDA approved gedatolisib/fulvestrant, with or without palbociclib, for hormone receptor–positive advanced breast cancer without a PIK3CA mutation.
Read our recap of top phase 1 and 2 breast cancer data highlights that may lead to further clinical research and developments.
Read our recap of the top phase 3 breast cancer data announcements and highlights that may make waves in the future of breast cancer management.
In case you missed any, check out our recap of the episodes of OncLive On Air that aired in June 2026.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to Pelareorep in Pretreated SCAC
2
PRAME-Directed Therapies Advance Melanoma Treatment Across Clinical Settings
3
META 10-19 Elicits High Complete Response Rate at Ultra-Low Doses in High-Risk R/R DLBCL
4
Sonrotoclax and Next-Generation BCL-2 Inhibitors for Treating CLL
5